Researchers at the Texas A&M University have developed a system that allows scientists to control the behavior of genetically engineered cells using caffeine. The study was published in the Journal of the American Chemical Society.

The technology, called CODS (Caffeine-Operated Dissociation System), functions as a molecular “switch” designed with the help of artificial intelligence. Its purpose is to control when proteins inside a cell bind together or separate, enabling cellular processes to be turned on or off on demand.

Unlike earlier approaches in which caffeine was used to bring proteins together, the new system works in reverse. When caffeine is added, protein complexes break apart. In the absence of caffeine, the proteins remain connected and active. As a result, caffeine acts as an external signal that regulates intracellular activity.

The platform is based on AI-designed synthetic proteins engineered to respond specifically to caffeine. Researchers used advanced protein-modeling algorithms and high-performance computing to create a molecular “lock” that opens when exposed to caffeine.

The system operates at very low caffeine concentrations, responds within minutes, and can be switched on and off repeatedly.

Scientists tested CODS in three different biological applications.

In the first experiment, the system controlled gene activity. Without caffeine, the target gene remained active. After caffeine was introduced, gene activity dropped sharply, and once caffeine was removed, normal function returned.

In the second application, CODS was integrated into a programmed cell-death pathway. The addition of caffeine triggered pyroptosis, an inflammatory form of cell death. This approach could be useful for studying inflammation and developing controllable cell-based therapies.

Perhaps the most significant application involved CAR-T Cell Therapy, a powerful cancer treatment that uses engineered immune cells. Although CAR-T therapies have demonstrated remarkable effectiveness, they can sometimes cause severe side effects due to excessive immune activation.

The CODS system allowed researchers to temporarily switch off CAR-T cell activity using caffeine, potentially reducing the risk of complications without eliminating the therapeutic cells themselves.

The authors emphasize that caffeine is not being used as a medicine. Instead, it serves as a convenient, widely available, and relatively safe signal for controlling bioengineered cellular systems.

In the future, technologies such as CODS could pave the way for “programmable” cell therapies that physicians can regulate even after they have been administered to patients, offering greater precision and safety in treatments for cancer and other diseases.